An experiment in mice has separated two features of Alzheimer’s disease that are often treated as one problem. Amyloid plaques remained in place, yet sleep improved sharply when researchers removed most of the brain’s microglia—the immune cells that react to those plaques.
The sleep clue changed the question
Disturbed sleep is part of the Alzheimer’s picture, but the biology behind it has been difficult to pin down. Amyloid plaques are an obvious suspect: they accumulate in the brain and sit at the centre of much Alzheimer’s research. The new work asks whether the plaques themselves interrupt sleep, or whether the brain’s response to them does the damage.
Microglia patrol the brain, clear debris and respond to injury. Around amyloid plaques, they can also become highly active. The researchers’ result points toward that broader immune reaction as a possible driver of lost sleep in their Alzheimer’s mouse model. Plaques may be the spark; the surrounding cellular response may be what changes sleep across the brain.
That distinction matters because plaque burden alone did not track neatly with the sleep problem. The mice showed substantial disruption when plaques first appeared, and the disruption did not simply rise in proportion as plaques became more extensive. That gave the team a reason to look beyond plaque quantity.
What the experiment found
Researchers at the University of Kentucky compared mice engineered to develop Alzheimer’s-like amyloid plaques with normally aging mice. They recorded brain and muscle activity at six months, when plaques had begun to appear, and again at 18 months, when plaque levels were much higher. Those recordings let the team distinguish waking, REM sleep and non-REM sleep.
The two kinds of aging produced different patterns. Normal aging mainly reduced REM sleep. In the Alzheimer’s model, the clearer loss appeared in non-REM sleep. Most strikingly, the sleep disruption was already pronounced at six months and remained similar at 18 months even though plaque burden had more than doubled.
The team then used pexidartinib to reduce the population of microglia by about 87 percent. The treated mice slept more than two additional hours during a 24-hour period. Their non-REM sleep came in longer stretches. Yet their amyloid plaques did not disappear. Changing the immune-cell population changed sleep without changing the feature that originally set off the immune response.
A mechanism to test, not a treatment
The cleanest reading is also the most interesting one: in this mouse model, microglia were necessary for much of the sleep disruption associated with amyloid pathology. The experiment does not show that plaques are harmless, nor does it establish that microglia cause sleep loss in people with Alzheimer’s disease. It isolates one biological link in animals.
It also does not make microglia simple villains. These cells perform essential maintenance and defence work in the brain. Removing most of them was an experimental tool that helped reveal cause and effect; it is not a practical instruction for patient care. The study offers a target for further investigation, not a reason to use pexidartinib for sleep or Alzheimer’s disease.
Nor did the experiment test whether recovering sleep improves memory or slows disease progression. Those are separate questions. The result is valuable because it narrows the field: future studies can examine which microglial signals alter sleep and whether those signals can be moderated without removing the cells themselves.
What researchers can do next
The researchers are exploring a more precise strategy: calming overactive microglia while preserving their useful functions. The report names metformin and stiripentol among the existing drugs being examined for their effects on this immune activity. That work is still experimental, and it will need to establish both benefit and safety before moving the idea closer to human care.
The distinct EEG patterns are another lead. Because the researchers could tell normal aging from Alzheimer’s-like pathology through differences in REM and non-REM sleep, they see potential in portable EEG monitoring. Whether those signatures are reliable in people—and useful for detection outside a laboratory—remains to be tested.
For readers, the immediate takeaway is not a new remedy. It is a sharper picture of the problem: sleep loss in Alzheimer’s may depend on how the brain reacts to plaques, not only on how many plaques are present. That gives researchers a concrete mechanism to challenge in the next round of experiments.
Three things to remember
- Sleep disruption did not rise as plaque burden increased in the mice.
- Removing about 87 percent of microglia restored more than two hours of sleep.
- The experiment identifies a mechanism to test; it is not a human treatment.
Source
This analysis is based on Alzheimer’s breakthrough: Scientists restore two hours of sleep without clearing brain plaques from ScienceDaily Healthy Aging. Read the original report for full context.
Health note: This was a mouse study. It identifies a biological mechanism to investigate, not a treatment for people.